AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26220763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 26220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium supplements)
Number of subjects: 199
Study 26220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and Placebo
Number of subjects: 199
Study 24983746 — intervention group
Group type: EXPERIMENTAL
Intervention: Semagacestat (100 mg and 140 mg)
Number of subjects: 1537
Study 24983746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1537
Study 23726675 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 207
Study 23726675 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol 50mg
Number of subjects: 207
Study 23726675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 19892338 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy (group 1)
Number of subjects: 110
Study 19892338 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (group 2)
Number of subjects: 110
Study 19892338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 110
Study 18370880 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost treatment
Number of subjects: 22
Study 16822992 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (ECF regimen: epirubicin 50 mg/m², cisplatin 60 mg/m², fluorouracil 200 mg/m²/day for 21 days) and surgery
Number of subjects: 503
Study 16822992 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 503
Study 16822992 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (ECF regimen)
Number of subjects: 503
Study 14572521 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS over left DLPFC
Number of subjects: 16
Study 14572521 — intervention group
Group type: COMPARATOR
Intervention: Baseline without stimulation
Number of subjects: 16
Study 14572521 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS over right DLPFC
Number of subjects: 16
Study 14572521 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS over right cerebellum
Number of subjects: 16
Study 14572521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS over left DLPFC
Number of subjects: 16
Study 10742350 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 182
Study 10742350 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning alarm
Number of subjects: 182
Study 10742350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 8956299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine infusion from isolation of aorta until end of surgery (group A)
Number of subjects: 16
Study 8956299 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dopamine infusion over the same surgical course (group B)
Number of subjects: 16
Study 1286501 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum dose of 1 mg, administered intravenously at 0.2 mg at 1-minute intervals)
Number of subjects: 172
Study 1286501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml administered at 1-minute intervals)
Number of subjects: 172
Study 1286501 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 172
Study 1286501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 3927551 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide (1 mg per day, subcutaneous injection)
Number of subjects: 21
Study 3927551 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) (3 mg per day, oral)
Number of subjects: 21
Study 3927551 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide
Number of subjects: 21
Study 3927551 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 21
Study 31266016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango argentino
Number of subjects: 29
Study 31266016 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 29
Study 29588062 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity aerobic exercise
Number of subjects: 68
Study 29588062 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 35)
Number of subjects: 68
Study 27189180 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning EDUCAGUIA (educational games with hypothetical clinical scenarios in a virtual environment)
Number of subjects: 394
Study 27189180 — intervention group
Group type: COMPARATOR
Intervention: Usual dissemination strategy by e-mail (Control group)
Number of subjects: 394
Study 23695648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (30 min of moderate-intensity treadmill exercise, followed by resistance and stretching exercises, performed three times a week for 6 months)
Number of subjects: 30
Study 23695648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30
Study 23695648 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 30
Study 22646631 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling to an esophageal temperature of 33.5°C for 72 hours, followed by slow rewarming
Number of subjects: 208
Study 22646631 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study 22646631 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 208
Study 20798395 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive testing (NIT) for sexually transmitted infections (STI)
Number of subjects: 391
Study 20798395 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) STI testing with genital examination
Number of subjects: 391
Study 18850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-focused imagery
Number of subjects: 314
Study 18850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation-focused imagery
Number of subjects: 314
Study 18850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease of imagery (mediator)
Number of subjects: 314
Study 18850394 — intervention group
Group type: COMPARATOR
Intervention: Control (no imagery)
Number of subjects: 314
Study 15607841 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 1175
Study 12120779 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etching primer system)
Number of subjects: 0
Study 12120779 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (single-bottle adhesive system with total-etch wet bonding technique)
Number of subjects: 0
Study 10453373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (maximum dose 22 mg/day)
Number of subjects: 64
Study 10453373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10453373 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 64
Study 7598065 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (1.47 g protein.kg body cell mass‐1.d‐1)
Number of subjects: 0
Study 7598065 — intervention group
Group type: COMPARATOR
Intervention: Adequate-protein diet (2.94 g protein.kg body cell mass‐1.d‐1)
Number of subjects: 0
Study 2087856 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (20:121 watts, rest:work 1:1 min)
Number of subjects: 18
Study 2087856 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (83 watts)
Number of subjects: 18
Study 388295 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 40
Study 388295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31823206 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Low Dose Preservative-Free Hydrocortisone
Number of subjects: 0
Study 30640654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidurally applied levobupivacaine
Number of subjects: 70
Study 30640654 — intervention group
Group type: COMPARATOR
Intervention: Intravenously applied morphine
Number of subjects: 70
Study 30640654 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 70
Study 27653753 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-training programme with telephone consultation
Number of subjects: 116
Study 27653753 — intervention group
Group type: COMPARATOR
Intervention: Written educational materials and social telephone follow-ups (Control)
Number of subjects: 116
Study 25880004 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 271
Study 25880004 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX
Number of subjects: 271
Study 24306438 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of a video of an actor performing in a CW environment
Number of subjects: 3
Study 24306438 — intervention group
Group type: COMPARATOR
Intervention: Physical practice only group
Number of subjects: 3
Study 22954642 — intervention group
Group type: EXPERIMENTAL
Intervention: PURPLE materials (DVD and booklet)
Number of subjects: 201
Study 22954642 — intervention group
Group type: COMPARATOR
Intervention: Analogous control materials on infant safety
Number of subjects: 201
Study 19683639 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the left atrial appendage (LAA) and subsequent discontinuation of warfarin (n=463)
Number of subjects: 707
Study 19683639 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment with a target international normalised ratio between 2.0 and 3.0 (n=244)
Number of subjects: 707
Study 19683639 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the left atrial appendage (LAA)
Number of subjects: 707
Study 19683639 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment
Number of subjects: 707
Study 17295727 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence in ability to change (single-item measure)
Number of subjects: 312
Study 17295727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to abstain (single-item measure)
Number of subjects: 312
Study 17295727 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-item measures of readiness, importance, and intention to cut down
Number of subjects: 312
Study 16320926 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (7.5 g in 500 ml of cardioplegic solution)
Number of subjects: 28
Study 11910365 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate generation of the allocation sequence
Number of subjects: 383
Study 11910365 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate allocation concealment
Number of subjects: 383
Study 11910365 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials that were double blind
Number of subjects: 383
Study 11910365 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological quality improvement in trials
Number of subjects: 383
Study 9791527 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute video intervention to increase safety awareness
Number of subjects: 80
Study 9791527 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group parents)
Number of subjects: 80
Study 9791527 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute video intervention
Number of subjects: 80
Study 7714648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic sequential leg compression devices (PSLCDs)
Number of subjects: 304
Study 7714648 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 304
Study 2522110 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride treatment
Number of subjects: 8
Study 2522110 — intervention group
Group type: COMPARATOR
Intervention: Lithium treatment
Number of subjects: 8
Study 493897 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent exercises
Number of subjects: 42
Study 493897 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 42
Study 31982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil chemotaxis activity in survivors
Number of subjects: 136
Study 31982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neutrophil chemotaxis activity with mHLA-DR, CD-11b expression, presepsin, and SOFA score
Number of subjects: 136
Study 31982695 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased neutrophil chemotaxis activity
Number of subjects: 136
Study 29886470 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS III
Number of subjects: 76
Study 29886470 — intervention group
Group type: COMPARATOR
Intervention: ORS I
Number of subjects: 76
Study 25425655 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days)
Number of subjects: 92
Study 25425655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 25425655 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 92
Study 24885593 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Work Performance Questionnaire (IWPQ)
Number of subjects: 260
Study 22237275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical fixed-point traction manipulation
Number of subjects: 84
Study 22237275 — intervention group
Group type: COMPARATOR
Intervention: Cervical computer traction
Number of subjects: 84
Study 20346113 — intervention group
Group type: COMPARATOR
Intervention: Clothed manikin (three layers)
Number of subjects: 48
Study 20346113 — intervention group
Group type: EXPERIMENTAL
Intervention: Undressed manikin
Number of subjects: 48
Study 18366264 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 832
Study 15845879 — intervention group
Group type: EXPERIMENTAL
Intervention: Water deprivation for 24 hours
Number of subjects: 16
Study 15845879 — intervention group
Group type: COMPARATOR
Intervention: Normal water intake
Number of subjects: 16
Study 12428824 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (60 minutes, 5 days a week for 4 weeks)
Number of subjects: 62
Study 12428824 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (60 minutes, 5 days a week for 4 weeks)
Number of subjects: 62
Study 12428824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training (5 days a week for 4 weeks)
Number of subjects: 62
Study 12428824 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS & Exercise (5 days a week for 4 weeks)
Number of subjects: 62
Study 10959785 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal Scaling (CS)
Number of subjects: 39
Study 10959785 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival Scaling (SS)
Number of subjects: 39
Study 10959785 — intervention group
Group type: COMPARATOR
Intervention: Coronal Scaling (CS) and Subgingival Scaling (SS)
Number of subjects: 39
Study 8776122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal pins
Number of subjects: 0
Study 8776122 — intervention group
Group type: COMPARATOR
Intervention: Synthetic braided absorbable suture (Control)
Number of subjects: 0
Study 2060255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927 (1.2 mg) q.i.d.
Number of subjects: 16
Study 2060255 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8% sezolamide (1.1 mg) q.i.d.
Number of subjects: 16
Study 2060255 — intervention group
Group type: COMPARATOR
Intervention: Common vehicle q.i.d.
Number of subjects: 16
Study 6403135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 8
Study 6403135 — intervention group
Group type: COMPARATOR
Intervention: Intravenous glucose
Number of subjects: 8
Study 31124272 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (100 ± 20 μg/kg dose)
Number of subjects: 0
Study 31124272 — intervention group
Group type: COMPARATOR
Intervention: Emicizumab prophylaxis
Number of subjects: 0
Study 29756595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg
Number of subjects: 0
Study 29756595 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 0
Study 27139057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (54 Gy plus capecitabine)
Number of subjects: 449
Study 27139057 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (1000 mg/m2 weekly of gemcitabine)
Number of subjects: 449
Study 27139057 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (100 mg/d)
Number of subjects: 449
Study 27139057 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 449
Study 27139057 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 449
Study 26017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (45 mg) applied to mastectomy skin at the time of surgical dressing
Number of subjects: 165
Study 26017589 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied to mastectomy skin at the time of surgical dressing
Number of subjects: 165
Study 26017589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Number of subjects: 165
Study 26017589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 22236639 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 68
Study 22236639 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound therapy (Control)
Number of subjects: 68
Study 20068494 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(-1) body mass)
Number of subjects: 9
Study 20068494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 20068494 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 9
Study 20068494 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 9
Study 20068494 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day (evening vs morning)
Number of subjects: 9
Study 18719863 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC) with or without endoscopic sphincterotomy (ES)
Number of subjects: 0
Study 18719863 — intervention group
Group type: EXPERIMENTAL
Intervention: Open bile duct surgery
Number of subjects: 0
Study 18719863 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic removal of CBDS
Number of subjects: 0
Study 18719863 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography or magnetic resonance cholangiopancreatography
Number of subjects: 0
Study 15831804 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured resting metabolic rate (RMR) using indirect calorimetry and energy cost of walking at 5.6 km/h in a subsample of 49 men and 49 women.
Number of subjects: 769
Study 15831804 — intervention group
Group type: EXPERIMENTAL
Intervention: Using measured or predicted RMR as a correction factor for estimating energy cost of walking.
Number of subjects: 769
Study 11838628 — intervention group
Group type: COMPARATOR
Intervention: Sertraline treatment (50 to 200 mg/day) during the acute phase
Number of subjects: 359
Study 11838628 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment with sertraline
Number of subjects: 359
Study 11838628 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of sertraline (double-blind)
Number of subjects: 359
Study 10416848 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol prompting correct lifting posture
Number of subjects: 0
Study 10416848 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 7677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Glutamine (GLN) + Diet (DIET)
Number of subjects: 47
Study 7677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term therapy with GH + GLN + DIET
Number of subjects: 47
Study 2119392 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg leuprolide acetate (GnRH agonist)
Number of subjects: 14
Study 2119392 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU hCG
Number of subjects: 14
Study 6195025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermally injected bleomycin in saline and oil
Number of subjects: 62
Study 6195025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31959226 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA) group (active points related to cLBP)
Number of subjects: 0
Study 31959226 — intervention group
Group type: COMPARATOR
Intervention: Comparison group-1 (non-active points, unrelated to cLBP)
Number of subjects: 0
Study 31959226 — intervention group
Group type: COMPARATOR
Intervention: Comparison group-2 (enhanced educational control, an educational booklet on cLBP)
Number of subjects: 0
Study 31263231 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - received exploration feedback during the Test phase.
Number of subjects: 0
Study 31263231 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - did not receive exploration feedback during the Test phase.
Number of subjects: 0
Study 28625282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise program (treadmill running, >70% to 85% of maximal oxygen consumption, 3 times a week for 24 weeks)
Number of subjects: 433
Study 28625282 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 433
Study 27484017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oralair® (8200 BAU)
Number of subjects: 33
Study 27484017 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax® (6200 BAU)
Number of subjects: 33
Study 27484017 — intervention group
Group type: EXPERIMENTAL
Intervention: Staloral® (12000 BAU/ml)
Number of subjects: 33
Study 27484017 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluprick® (10300 BAU/ml)
Number of subjects: 33
Study 27484017 — intervention group
Group type: COMPARATOR
Intervention: Reference extract (10000 BAU/ml)
Number of subjects: 33
Study 23957902 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-image intervention
Number of subjects: 7000
Study 23957902 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 7000